Clinical Trial

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Recruiting
View on ClinicalTrials.gov →
Summary
ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.
Protocol Amendment History 5 changes
minor Trial arms changed: 1 -> 2 2026-07-31
notable Trial sites expanded: 18 -> 29 locations 2026-07-31
notable Trial sites expanded: 15 -> 18 locations 2026-06-13
notable Trial sites expanded: 10 -> 15 locations 2026-06-02
notable Trial sites expanded: 5 -> 10 locations 2026-04-24
Trial Details
NCT Number NCT07294170
Lead Sponsor argenx
Conditions Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG), AChR-Ab Seropositive Generalized Myasthenia Gravis
Enrollment 70 participants
Start Date 2025-12-19
Primary Completion 2028-03-07 (estimated)
Study Completion 2028-03-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-30